

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

by Eduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, Lucas C. Zarling, Brenda M. Sandmaier, Filippo Milano, Gary Schoch, Chris Davis, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, and Roland B. Walter

Received: June 26, 2022.

Accepted: September 14, 2022.

Citation: Eduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, Lucas C. Zarling, Brenda M. Sandmaier, Filippo Milano, Gary Schoch, Chris Davis, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, and Roland B. Walter. Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Haematologica. 2022 Sept 22. doi: 10.3324/haematol.2022.281631 [Epub ahead of print]

Publisher's Disclaimer.

E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Running head: MRD and post-HCT outcome prediction in AML

Eduardo Rodríguez-Arbolí,^{1,2} Megan Othus,³ Corentin Orvain,¹
Lucas C. Zarling,⁴ Brenda M. Sandmaier,^{1,5} Filippo Milano,^{1,5} Gary Schoch,¹
Chris Davis,¹ H. Joachim Deeg,^{1,5} Frederick R. Appelbaum,^{1,5}
Rainer Storb,^{1,5} Roland B. Walter^{1,6,7,8}

¹Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; ²Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Seville, Seville, Spain; ³Public Health Science Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; ⁴Department of Medicine, Residency Program, University of Washington, Seattle, WA, USA; ⁵Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; ⁶Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; ⁷Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA; ⁸Department of Epidemiology, University of Washington, Seattle, WA, USA.

Competing interests: The authors declare no competing financial interests.

Authorship contributions: E.R.A. contributed to the collection and assembly of data, data analyses and interpretation, and drafting of the manuscript. M.O. conducted all statistical analyses and participated in data interpretation and drafting of the manuscript. C.O., L.C.Z., G.S., and C.D. contributed to the collection and assembly of data. B.M.S., F.M., H.J.D., F.R.A., and R.S. contributed to the provision of study material, patient recruitment, and acquisition of data. R.B.W. conceptualized and designed this study and participated in data analysis and interpretation and drafting of the manuscript. All authors revised the manuscript critically and gave final approval to submit for publication.

Data sharing statement: Original data can be made available upon request to the corresponding author (rwalter@fredhutch.org).

Acknowledgments: Research reported in this publication was supported by grants P01-CA078902, P01-CA018029, and P30-CA015704 from the National Cancer Institute/National Institutes of Health (NCI/NIH), Bethesda, MD, USA. The authors acknowledge the excellent care provided by the physicians and nurses of the HCT teams, the staff in the Long-Term Follow-up office at the Fred Hutchinson Cancer Center, and the patients for participating in our research protocols.

Address for correspondence: Roland B. Walter, MD PhD MS; Clinical Research Division,
Fred Hutchinson Cancer Center; 1100 Fairview Ave N, D2-190;
Seattle, WA 98109-1024, USA
Phone: +1-206-667-3599; Fax: +1-206-667-5510; E-mail: rwalter@fredhutch.org

Word count: Text: 1,497 words; Figures/Tables: 0/2; Supplementary Figures/Tables: 1/2; References: 15

Measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) is strongly associated with relapse risk and survival in acute myeloid leukemia (AML).¹⁻⁴ However, association is not prediction.^{5, 6} In association studies, inferences about a risk factor (e.g. MRD) are made at the population level, not the individual patient level.^{6, 7} This difference is important because, for clinical decision-making, we are most interested in predicting outcomes for a particular patient. This ability is evaluated with classification models. Good association is usually necessary but not sufficient for good classification. The degree to which MRD data improve post-HCT outcome prediction in adults with AML is unknown.

To address this, we studied all adults ≥ 18 years with AML who received a first allograft while in first or second remission between 4/2006 and 5/2021 and underwent bone marrow MRD testing by multiparameter (10-color) flow cytometry (MFC) before and approximately 1 month after HCT.⁸ The MRD assay methodology has remained essentially unchanged throughout the study period, with stable assay performance over time.⁸ MRD was identified using a “difference from normal” approach, with the assay detecting MRD in most cases to a level of 0.1% and in progressively smaller subsets of patients as the level of MRD decreases below that level.⁸ Disease risk and treatment response was assessed via 2017 European LeukemiaNet (ELN) criteria⁹ except that relapse was defined as emergence of $>5\%$ blasts by morphology or MFC in blood or marrow, emergence of cytogenetic abnormalities seen previously, or presence/emergence of any level of disease if leading to therapeutic intervention.⁸ Our retrospective analysis was approved by the Fred Hutch’s Institutional Review Board. Data follow-up was current as of February 10, 2022.

Overall survival (OS) and relapse-free survival (RFS) were estimated using the Kaplan-Meier method. Probabilities of relapse and non-relapse mortality (NRM) were summarized using cumulative incidence estimates, with death without prior relapse considered a competing risk for relapse and relapse being a competing risk for NRM. Following our previous approach⁸ and supported by findings from restricted cubic spline models and maximally selected rank statistics (**Supplemental Figure 1**), any detectable level of MRD was considered positive. We used Cox regression to assess the association between OS or RFS and covariates of interest, whereas cause-specific Cox regression models were used for relapse and NRM in the setting of competing risks. We used the C-statistic to quantify a model’s ability to predict outcomes, with values of 0.6-0.7, 0.7-0.8, and 0.8-0.9 considered as poor, fair, and good. Statistical analyses were performed using R (<http://www.r-project.org>).

We identified 979 patients for study inclusion (**Table 1**). 460 deaths, 308 relapses, and 193 NRM events contributed to estimates for relapse, OS, RFS, and NRM with a median (range) follow-up after HCT among survivors of 62 (3-182) months. Compared to adults without MRD, those with MRD had a significantly increased relapse risk (hazard ratio [HR]: 4.28 [95% confidence interval: 3.40-5.40], $P<0.001$), shorter RFS (HR: 3.11 [2.57-3.76], $P<0.001$), and shorter OS (HR: 2.65 [2.18-3.23], $P<0.001$). Besides pre-HCT MRD status, several other factors were associated with relapse, RFS, OS, and/or NRM (**Supplemental Table 1**).

We then assessed the ability of covariates to predict relapse, RFS, and OS in individual patients. In univariate analyses, pre-HCT MRD status was the strongest (albeit poor) individual predictor for relapse, RFS, and OS (C-statistics: 0.64 [relapse], 0.60 [RFS], 0.59 [OS]; **Table 2**). Comparable results were obtained with the ELN-recommended $\geq 0.1\%$ MRD positivity threshold (C-statistics: 0.61, 0.58, 0.57). A basic multivariable model that included age, cytogenetic risk at diagnosis, remission number, time between most recent remission and HCT, Karnofsky score, neutrophil recovery before HCT, conditioning intensity, and secondary AML status yielded C-statistics of 0.64, 0.62, and 0.62 for relapse, RFS, and OS (**Table 2**). Inclusion of pre-HCT cytogenetic data (normalized vs. not normalized for patients presenting with abnormal karyotypes), which we very recently found to provide complementary information to flow cytometric MRD data despite its low sensitivity,¹⁰ improved models only minimally, yielding C-statistics of 0.66, 0.63, and 0.63 for relapse, RFS, and OS. The prediction accuracy could be further improved when information from pre-HCT MRD testing was included (C-statistics of 0.70, 0.66, and 0.65 for relapse, RFS, and OS; C-statistics using ELN cut-off: 0.70, 0.67, 0.65). In contrast, once the pre-HCT MRD status was included, adding pre-HCT cytogenetic data did not further improve the models' predictive ability (**Table 2**).

In our models for relapse, RFS, and OS, we identified a significant interaction between pre-HCT MRD status and conditioning intensity, with similar outcomes for MRD-positive patients across regimens but better outcomes for MRD-negative patients with myeloablative conditioning. However, including this interaction term in models only minimally improved the predictive performance for relapse (C-statistic 0.71 vs. 0.70) but not for RFS or OS.

Currently, there is focus on pre-HCT testing because of the perceived value in using data for decision-making regarding use/not use of allogeneic HCT and specifics of the allografting approach. However, there is interest in MRD-directed post-HCT interventions, for which early post-HCT MRD data could be useful. That is because our recent data indicated that, across conditioning intensities, combined use of pre-HCT MRD data and early post-HCT MRD data, obtained 20-40 days after HCT (“peri-HCT MRD dynamics”), improves risk assessment over isolated pre-HCT MRD assessments and identifies 4 groups of patients with distinct clinical outcomes.⁸ We therefore performed a second set of analyses, restricting the dataset to 926 patients with pre- and early post-HCT MRD data available (**Table 1**). Patients in the MRD^{neg}/MRD^{pos} group (n=21) were excluded from these models due to unstable hazard ratio estimates caused by most patients in the subgroup having relapsed by time 0 of the relapse and RFS measurements. In day +40 landmark analyses, peri-HCT MRD dynamics were strongly associated with relapse, RFS, and OS and, weakly, with NRM; as in the entire cohort, several other factors were associated with relapse, RFS, OS, and/or NRM in this patient subset (**Supplemental Table 2**). In univariate models, peri-HCT MRD dynamics were equally accurate as pre-HCT MRD data for the prediction of relapse (C-statistic=0.70), RFS (C-statistic=0.63), and OS (C-statistic=0.61; **Table 2**). Likewise, C-statistic values in multivariable models remained unchanged when data on peri-HCT MRD dynamics rather than pre-HCT MRD status were included (0.71, 0.68, and 0.67 for the prediction of relapse, RFS, and OS).

We previously reported that detailed molecular data modestly improve the prediction of therapeutic resistance or survival in adults receiving intensive AML chemotherapy.¹¹ We therefore considered that refined cytogenetic/molecular risk categorization could improve post-HCT outcome prediction. As a limitation of our dataset, molecular data sufficient for risk classification based on ELN 2017 criteria were only available for 260 patients in the more recent period since 2016 when extended molecular profiling became routine at our institution. In this latter subset, the addition of ELN 2017 cytogenetic/molecular disease risk to a multivariable model including pre-HCT MRD status yielded C-statistics of 0.70, 0.69 and 0.68 for relapse, RFS and OS.

Decision-making in most areas of medicine, including HCT, entails important uncertainties.¹² While MRD data increased the accuracy of outcome prediction in our cohort, our finding of C-statistics not exceeding 0.71 for relapse, 0.68 for RFS, and 0.67 for OS highlights that our ability to predict important outcomes in adults with AML undergoing allogeneic HCT is limited even with MRD information available. This is

reminiscent of findings we obtained when building multivariable models to predict outcomes after intensive AML chemotherapy.¹³ With this, our data caution against over-reliance on MRD data (or any other routine clinical information) to guide decision-making and prognostication in individual AML patients considered for allografting or post-HCT interventions.

Several reasons may underlie the modest contribution of MRD data to post-HCT outcome prediction. First, there are inherent limitations to MRD testing that can result in patient misclassification.¹⁴ Second, it is conceivable that MRD used as a binary readout rather than continuous biomarker could decrease prediction accuracy. However, we explored this through non-linear modelling of relationships between MRD and post-HCT endpoints with cubic spline functions and did not find noticeable differences in relapse or survival risks across MRD levels. This suggests the consideration of any detectable level of MRD as positive did not negatively impact models' predictive accuracies. Third, since different MRD test modalities provide complementary rather than congruent prognostic information,¹⁵ the incorporation of molecular MRD data may improve outcome prediction. Unfortunately, molecular MRD testing was not routine part of the pre-HCT evaluation in the study period. Fourth, because of the lack of detailed molecular data, we could not assess a possible interaction between MRD and genetic/molecular disease risk. Fifth, NRM represents a major contribution to mortality after allogeneic HCT. Imperfectly accounted for in competing risks analyses, NRM events may interfere with the ability to predict relapse and survival outcomes with MRD data. Lastly, sustained AML remission after allogeneic HCT largely depends on graft-versus-leukemia (GVL) effects. Pre-HCT and early post-HCT MRD primarily measure AML sensitivity to prior chemotherapy and conditioning regimens and may not predict immune-mediated eradication of leukemic cells. The identification of robust immune biomarkers predicting GVL effects after allogeneic HCT could help refine relapse risk stratification.

REFERENCES

1. Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. *Leukemia*. 2017;31(7):1482-1490.
2. Short NJ, Zhou S, Fu C, et al. Impact of measurable residual disease on survival outcomes in patients with acute myeloid leukemia: a meta-analysis. *JAMA Oncol*. 2020;6(12):1890-1899.
3. Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. *Blood*. 2021;138(26):2753-2767.
4. Hourigan CS, Dillon LW, Gui G, et al. Pre-MEASURE: multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission. *J Clin Oncol*. 2022;40(16 Suppl):7006.
5. Kattan MW. Judging new markers by their ability to improve predictive accuracy. *J Natl Cancer Inst*. 2003;95(9):634-635.
6. Feng Z. Classification versus association models: should the same methods apply? *Scand J Clin Lab Invest Suppl*. 2010;242:53-58.
7. Walter RB, Estey EH. Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: limitations of predictive models. *Blood Rev*. 2020;44:100679.
8. Paras G, Morsink LM, Othus M, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. *Blood*. 2022;139(11):1694-1706.
9. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
10. Orvain C, Wilson JA, Fang M, et al. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. *Haematologica*. 2022 Aug 4. [Epub ahead of print]
11. Walter RB, Othus M, Paietta EM, et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. *Leukemia*. 2015;29(10):2104-2107.
12. Dhawale T, Steuten LM, Deeg HJ. Uncertainty of physicians and patients in medical decision making. *Biol Blood Marrow Transplant*. 2017;23(6):865-869.
13. Othus M, Wood BL, Stirewalt DL, et al. Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. *Leukemia*. 2016;30(10):2080-2083.
14. Othus M, Gale RP, Hourigan CS, Walter RB. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. *Bone Marrow Transplant*. 2020;55(5):843-850.
15. Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. *N Engl J Med*. 2018;378(13):1189-1199.

TABLE 1. Demographic and clinical characteristics of the study cohorts

	Pre-HCT MRD cohort (n=979)	Peri-HCT MRD dynamics cohort (n=926)
Median age at HCT (range), years	55 (18-81)	55 (18-81)
Male gender, n (%)	525 (54)	495 (53)
Median WBC at diagnosis (range), x10³/μL	8 (0-348)	8 (0-348)
2017 ELN cytogenetic risk*, n (%)		
Favorable	72 (7)	68 (7)
Intermediate	618 (63)	590 (64)
Adverse	251 (26)	231 (25)
Missing/Not reported	38 (4)	37 (4)
2017 ELN cytogenetic/molecular risk, n (%)		
Favorable	171 (17)	164 (18)
Intermediate	87 (9)	83 (9)
Adverse	128 (13)	121 (13)
Missing/Not reported	593 (61)	558 (60)
<i>NPM1</i> mutational status at diagnosis, n (%)		
Positive	142 (15)	134 (14)
Negative	441 (45)	422 (46)
Missing/Not reported	396 (40)	370 (40)
<i>FLT3</i>-ITD mutational status at diagnosis, n (%)		
Positive	172 (18)	162 (17)
Negative	451 (46)	429 (46)
Missing/Not reported	356 (36)	335 (36)
Secondary AML**, n (%)	257 (26)	239 (26)
Disease status at HCT, n (%)		
First remission	747 (76)	708 (76)
Second remission	232 (24)	218 (24)
Median remission duration before HCT (range), days	98 (7-788)	98 (7-788)
Recovered ANC before HCT***, n (%)	885 (90)	840 (91)
Recovered platelet count before HCT***, n (%)	691 (71)	656 (71)
Recovered peripheral blood counts before HCT***, n (%)	680 (69)	646 (70)
Pre-HCT Cytogenetics HCT, n (%)		
Normalized karyotype	387 (40)	363 (39)
Abnormal karyotype	161 (16)	151 (16)
Non-informative karyotype****	431 (44)	412 (44)
Pre-HCT MRD status, n (%)		

MRD ^{pos}	191 (20)	186 (20)
MRD ^{neg}	788 (80)	740 (80)
Post-HCT MRD status day +20-40, n (%)		
MRD ^{pos}	71 (7)	50 (5)
MRD ^{neg}	876 (89)	876 (95)
Not available	32 (3)	-
Peri-HCT MRD dynamics, n (%)		
MRD ^{pos} /MRD ^{pos}	50 (5)	50 (5)
MRD ^{pos} /MRD ^{neg}	136 (14)	136 (15)
MRD ^{neg} /MRD ^{neg}	740 (76)	740 (80)
MRD ^{neg} /MRD ^{pos}	21 (2)	-
Not available	32 (3)	-
Karnofsky score, % (range)	90 (40-100)	90 (50-100)
HCT Comorbidity Index, n (%)		
0-1	339 (35)	324 (35)
2-3	347 (35)	334 (36)
≥4	293 (30)	268 (29)
Conditioning intensity, n (%)		
MAC	583 (60)	558 (60)
Non-MAC	396 (40)	368 (40)
HLA matching, n (%)		
HLA-identical related donor	227 (23)	219 (24)
HLA-matched unrelated donor	482 (49)	456 (49)
1-2 allele/antigen mismatched unrelated donor	101 (10)	95 (10)
HLA-haploidentical donor	37 (4)	34 (4)
UCB	132 (13)	122 (13)
Source of stem cells, n (%)		
PB	766 (78)	728 (79)
BM	81 (8)	76 (8)
UCB	132 (13)	122 (13)
GVHD prophylaxis, n (%)		
CNI + MMF ± sirolimus	473 (48)	444 (48)
CNI + MTX ± other	370 (38)	352 (38)
PTCy	122 (12)	116 (13)
Other	14 (1)	14 (2)

*Risk stratification according to the presence of cytogenetic abnormalities only. **Secondary AML was defined as disease following an antecedent hematologic disorder or treatment with systemic chemotherapy, radiotherapy, or both for a different disorder. ***ANC ≥1,000/μL and platelets ≥100,000/μL. ****Normal cytogenetics in cytogenetically normal AML or missing cytogenetics at diagnosis. Abbreviations: AML, acute myeloid leukemia; ANC, absolute

neutrophil count; BM, bone marrow; CNI, calcineurin inhibitor; ELN, European LeukemiaNet; HCT, hematopoietic cell transplantation; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MRD, measurable residual disease; MTX, methotrexate; PB, peripheral blood; PTCy, post transplantation cyclophosphamide; UCB, umbilical cord blood; WBC, total white blood cell count.

TABLE 2. C-statistics for univariate and multivariate Cox regression analyses

Parameter	Pre-HCT MRD cohort (n=979)			Peri-HCT MRD dynamics cohort (n=926)		
	Relapse	RFS	OS	Relapse	RFS	OS
Univariate analyses						
Pre-HCT MRD status	0.64	0.60	0.59	0.66	0.62	0.60
Post-HCT MRD status day +20-40	-	-	-	0.57	0.55	0.54
Peri-HCT MRD dynamics	-	-	-	0.67	0.63	0.61
2017 ELN cytogenetic risk at diagnosis*	0.59	0.56	0.55	0.59	0.56	0.55
Pre-HCT cytogenetics**	0.57	0.56	0.56	0.57	0.57	0.57
Age at HCT	0.55	0.57	0.57	0.53	0.57	0.57
Time between CR and HCT	0.55	0.52	0.52	0.55	0.53	0.52
Conditioning (MAC vs. non-MAC)	0.54	0.56	0.55	0.52	0.55	0.55
Karnofsky score	0.54	0.55	0.55	0.54	0.55	0.55
<i>NPM1</i> mutational status at diagnosis	0.54	0.53	0.53	0.55	0.52	0.53
<i>FLT3</i> -ITD mutational status at diagnosis	0.54	0.52	0.51	0.54	0.51	0.50
Disease status at HCT (CR2 vs. CR1)	0.53	0.53	0.53	0.53	0.53	0.53
ANC recovery before HCT	0.52	0.52	0.52	0.52	0.52	0.52
Secondary AML*** (vs. de novo)	0.52	0.52	0.52	0.52	0.52	0.52
Multivariate analyses						
Basic covariates****	0.64	0.62	0.62	0.64	0.62	0.63
Basic covariates + <i>NPM1</i> / <i>FLT3</i> -ITD mutational status at diagnosis	0.64	0.62	0.62	0.64	0.62	0.63

Basic covariates + pre-HCT cytogenetics	0.66	0.63	0.63	0.65	0.64	0.64
Basic covariates + pre-HCT MRD status	0.69	0.66	0.65	0.70	0.68	0.66
Basic covariates + pre-HCT cytogenetics + pre-HCT MRD status	0.70	0.66	0.65	0.71	0.68	0.67
Basic covariates + pre-HCT cytogenetics + post-HCT MRD status day +20-40	-	-	-	0.67	0.66	0.65
Basic covariates + pre-HCT cytogenetics** + peri-HCT MRD dynamics	-	-	-	0.71	0.68	0.67

*Risk stratification according to the presence of cytogenetic abnormalities only. **Abnormal vs. normalized vs. missing/non-informative. ***Secondary AML was defined as disease following an antecedent hematologic disorder or treatment with systemic chemotherapy, radiotherapy, or both for a different disorder. ****Age at HCT, 2017 ELN cytogenetic risk at diagnosis (favorable vs. intermediate vs. adverse vs. unknown), remission (first vs. second), time between most recent CR and HCT, Karnofsky score, recovery of ANC before HCT to 1,000/ μ L (yes vs. no), conditioning intensity (MAC vs. non-MAC), secondary AML (vs. de novo). Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil count; CR, complete remission; ELN, European LeukemiaNet; HCT, hematopoietic cell transplantation; MAC, myeloablative conditioning; MRD, measurable residual disease; OS, overall survival; RFS, relapse-free survival.

SUPPLEMENTARY TABLE 1. Multivariate Cox regression models in the pre-HCT MRD cohort

Covariate	Relapse		RFS		OS		NRM	
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Pre-HCT MRD status								
MRD ^{reg}	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
MRD ^{pos}	3.6 (2.73-4.76)	<0.001	2.61 (2.08-3.29)	<0.001	2.05 (1.61-2.60)	<0.001	1.34 (0.87-2.07)	0.19
Age at HCT (per 10 years)	0.98 (0.88-1.09)	0.73	1.04 (0.96-1.14)	0.34	1.06 (0.96-1.16)	0.24	1.19 (1.02-1.38)	0.029
Type of AML								
De novo	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Secondary	0.71 (0.52-0.96)	0.028	0.85 (0.68-1.08)	0.18	0.95 (0.75-1.21)	0.69	1.13 (0.79-1.62)	0.49
2017 ELN cytogenetic risk*								
Favorable	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Intermediate	2.71 (1.26-5.84)	0.011	1.84 (1.10-3.08)	0.021	2.01 (1.14-3.55)	0.015	1.25 (0.61-2.56)	0.53
Adverse	4.62 (2.13-9.98)	<0.001	2.42 (1.43-4.09)	<0.001	2.66 (1.50-4.72)	<0.001	1.01 (0.47-2.14)	0.99
Missing/Not reported	4.67 (1.78-12.24)	0.002	2.56 (1.26-5.20)	0.009	2.84 (1.34-5.98)	0.006	1.26 (0.40-3.92)	0.70
Disease status at HCT								
First remission	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Second remission	1.46 (1.07-2.00)	0.016	1.38 (1.08-1.76)	0.011	1.46 (1.13-1.87)	0.0031	1.30 (0.87-1.96)	0.20
Days between CR and HCT	1.00 (1.00-1.00)	0.29	1.00 (1.00-1.00)	0.90	1.00 (1.00-1.00)	0.91	1.00 (1.00-1.00)	0.38
ANC recovery before HCT**								
Yes	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
No	1.45 (0.98-2.15)	0.06	1.41 (1.04-1.92)	0.028	1.31 (0.95-1.81)	0.10	1.35 (0.82-2.23)	0.24
Pre-HCT Cytogenetics HCT								
Normalized karyotype	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Abnormal karyotype	1.67 (1.19-2.34)	0.003	1.53 (1.16-2.01)	0.002	1.39 (1.04-1.86)	0.026	1.26 (0.79-2.02)	0.34
Non-informative karyotype***	1.02 (0.72-1.46)	0.90	1.00 (0.77-1.31)	0.97	1.07 (0.81-1.42)	0.62	0.93 (0.62-1.40)	0.72
Karnofsky score	1 (0.99-1.02)	0.87	0.99 (0.98-1.00)	0.16	0.99 (0.98-1.01)	0.28	0.98 (0.97-1.00)	0.02
Conditioning intensity								
MAC	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Non-MAC	1.69 (1.26-2.27)	<0.001	1.77 (1.40-2.23)	<0.001	1.62 (1.27-2.08)	<0.001	1.83 (1.25-2.68)	0.002

* Risk stratification according to the presence of cytogenetic abnormalities only. **ANC \geq 1,000/ μ L. ***Normal cytogenetics in cytogenetically-normal AML or missing cytogenetics at diagnosis. Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil count; CI, confidence interval; ELN, European LeukemiaNet; HCT, hematopoietic cell transplantation; HR, hazard ratio; MAC, myeloablative conditioning; MRD, measurable residual disease; NRM, non-relapse mortality; OS, overall survival; RFS, relapse-free survival.

SUPPLEMENTARY TABLE 2. Multivariate Cox regression models in the peri-HCT MRD dynamics cohort

Covariate	Relapse		RFS		OS		NRM	
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Peri-HCT MRD dynamics								
MRD ^{neg} /MRD ^{neg}	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
MRD ^{pos} /MRD ^{neg}	3.64 (2.64-5.02)	<0.001	2.64 (2.03-3.44)	<0.001	2.23 (1.70-2.92)	<0.001	1.42 (0.88-2.29)	0.15
MRD ^{pos} /MRD ^{pos}	9.25 (6.09-14.05)	<0.001	6.35 (4.37-9.22)	<0.001	3.00 (2.01-4.49)	<0.001	2.34 (0.91-6.03)	0.077
MRD ^{neg} /MRD ^{pos}	-	-	-	-	-	-	-	-
Age at HCT (per 10 years)	0.98 (0.88-1.10)	0.79	1.07 (0.98-1.18)	0.15	1.07 (0.97-1.19)	0.16	1.29 (1.09-1.52)	0.003
Type of AML								
De novo	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Secondary	0.66 (0.48-0.92)	0.015	0.81 (0.63-1.03)	0.091	0.94 (0.73-1.21)	0.64	1.10 (0.75-1.61)	0.62
2017 ELN cytogenetic risk*								
Favorable	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Intermediate	2.60 (1.09-6.24)	0.032	1.74 (0.99-3.03)	0.052	1.92 (1.04-3.52)	0.036	1.27 (0.60-2.69)	0.54
Adverse	4.30 (1.78-10.36)	0.001	2.12 (1.19-3.75)	0.01	2.37 (1.28-4.40)	0.006	0.85 (0.38-1.93)	0.70
Missing	4.48 (1.54-13.03)	0.006	2.49 (1.17-5.27)	0.017	2.72 (1.24-5.99)	0.013	1.45 (0.45-4.65)	0.53
Disease status at HCT								
First remission	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Second remission	1.29 (0.92-1.79)	0.14	1.28 (0.99-1.66)	0.061	1.37 (1.04-1.79)	0.023	1.38 (0.90-2.11)	0.14
Days between CR and HCT	1.00 (1.00-1.00)	0.20	1.00 (1.00-1.00)	0.79	1.00 (1.00-1.00)	0.87	1.00 (1.00-1.00)	0.31
ANC recovery before HCT**								
Yes	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
No	1.67 (1.11-2.52)	0.015	1.60 (1.16-2.21)	0.004	1.41 (1.00-1.98)	0.049	1.52 (0.90-2.56)	0.12
Pre-HCT Cytogenetics HCT								
Normalized karyotype	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Abnormal karyotype	1.72 (1.20-2.46)	0.003	1.62 (1.22-2.17)	0.001	1.42 (1.04-1.94)	0.028	1.41 (0.86-2.31)	0.17
Non-informative karyotype***	1.13 (0.78-1.65)	0.51	1.10 (0.83-1.46)	0.53	1.16 (0.86-1.56)	0.34	0.97 (0.63-1.49)	0.88
Karnofsky score	1.00 (0.99-1.02)	0.63	0.99 (0.98-1.01)	0.34	1.00 (0.98-1.01)	0.59	0.98 (0.97-1.00)	0.042
Conditioning intensity								
MAC	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Non-MAC	1.39 (1.02-1.90)	0.039	1.58 (1.24-2.02)	<0.001	1.53 (1.18-1.99)	0.001	1.81 (1.21-2.72)	0.004

* Risk stratification according to the presence of cytogenetic abnormalities only. **ANC $\geq 1,000/\mu\text{L}$. ***Normal cytogenetics in cytogenetically-normal AML or missing cytogenetics at diagnosis. Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil count; CI, confidence interval; ELN, European LeukemiaNet; HCT, hematopoietic cell transplantation; HR, hazard ratio; MAC, myeloablative conditioning; MRD, measurable residual disease; NRM, non-relapse mortality; OS, overall survival; RFS, relapse-free survival.



SUPPLEMENTARY FIGURE LEGEND

Supplementary Figure 1



Restricted cubic spline functions (left panels) and maximally selected rank statistics (right panels) for pre-HCT MRD levels and (A) time to relapse, (B) relapse-free survival, and (C) overall survival.

SUPPLEMENTARY FIGURE 1

A



B



C

